Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health

Reuters07-26

Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health

Klotho Neurosciences, Inc. (NASDAQ: KLTO) has announced plans to expand its development programs beyond neurology, with a focus on technologies that enhance brain function, muscle strength, bone health, and other indicators of longevity. The company is evaluating the acquisition of complementary technologies to support healthy brain function, organ health, and longevity, in addition to its core programs targeting neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. This expansion aims to slow biological aging and reduce age-related diseases by exploring genes and proteins such as alpha-Klotho, beta-Klotho, and FOXO3. CEO Dr. Joseph Sinkule emphasized the company's mission to identify and develop assets to delay age-related health outcomes through targeted research and intervention.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38172) on July 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2554901537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-26 09:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554901537","market":"fut","top_or_hot":-1,"title":"Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences, Inc.</a> (NASDAQ: KLTO) has announced plans to expand its development programs beyond neurology, with a focus on technologies that enhance brain function, muscle strength, bone health, and other indicators of longevity. The company is evaluating the acquisition of complementary technologies to support healthy brain function, organ health, and longevity, in addition to its core programs targeting neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. This expansion aims to slow biological aging and reduce age-related diseases by exploring genes and proteins such as alpha-Klotho, beta-Klotho, and FOXO3. CEO Dr. Joseph Sinkule emphasized the company's mission to identify and develop assets to delay age-related health outcomes through targeted research and intervention.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38172) on July 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKlotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-26 09:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences, Inc.</a> (NASDAQ: KLTO) has announced plans to expand its development programs beyond neurology, with a focus on technologies that enhance brain function, muscle strength, bone health, and other indicators of longevity. The company is evaluating the acquisition of complementary technologies to support healthy brain function, organ health, and longevity, in addition to its core programs targeting neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. This expansion aims to slow biological aging and reduce age-related diseases by exploring genes and proteins such as alpha-Klotho, beta-Klotho, and FOXO3. CEO Dr. Joseph Sinkule emphasized the company's mission to identify and develop assets to delay age-related health outcomes through targeted research and intervention.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38172) on July 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KLTO","symbol_name":"Klotho Neurosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250726:nNDL4kJN4S:1","article_id":"2554901537","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554901537","pubTimestamp":1753491966,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Klotho Neurosciences, Inc.  has announced plans to expand its development programs beyond neurology, with a focus on technologies that enhance brain function, muscle strength, bone health, and other indicators of longevity. The company is evaluating the acquisition of complementary technologies to support healthy brain function, organ health, and longevity, in addition to its core programs targeting neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. This expansion aims to slow biological aging and reduce age-related diseases by exploring genes and proteins such as alpha-Klotho, beta-Klotho, and FOXO3. CEO Dr. Joseph Sinkule emphasized the company's mission to identify and develop assets to delay age-related health outcomes through targeted research and intervention.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KLTO":"Klotho Neurosciences, Inc.","BK4139":"生物科技"},"translate_title":"Klotho Neurosciences Inc.扩展到神经病学之外，以提高寿命和健康","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLTO":0.9},"content_text":"Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health\n    \n\nKlotho Neurosciences, Inc. (NASDAQ: KLTO) has announced plans to expand its development programs beyond neurology, with a focus on technologies that enhance brain function, muscle strength, bone health, and other indicators of longevity. The company is evaluating the acquisition of complementary technologies to support healthy brain function, organ health, and longevity, in addition to its core programs targeting neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. This expansion aims to slow biological aging and reduce age-related diseases by exploring genes and proteins such as alpha-Klotho, beta-Klotho, and FOXO3. CEO Dr. Joseph Sinkule emphasized the company's mission to identify and develop assets to delay age-related health outcomes through targeted research and intervention.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38172) on July 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554901537","isCrawlerRequest":true}